Onesource Specialty Pharma Ltd

ESOP allotment and capital update

• Management Committee approved allotment of 900 equity shares under ONESOURCE ESOP 2021 to an eligible employee.
• Shares issued at par INR 1; exercise price INR 278; premium INR 277.
• Paid-up capital increases from INR 11,46,72,891 to INR 11,46,73,791.
• Total issued shares after issue: 11,46,73,791.
• ISIN: INE013P01021.
• Shares rank pari passu with existing shares.
• Date of issue: September 25, 2026.
• Details under Regulation 10(c) of SBEB Regulations 2021 attached.

OneSource Specialty Pharma Limited Trading Window Closed from October 01, 2026 until 48 hours after declaration of the financial results for the quarter ended September 30, 2026.

AGM Details

• AGM conducted in late September 2026; start time 5:00 PM, end 6:02 PM.
• Record date for voting observed in mid-September 2026.

Key Resolutions

• Ordinary: Adoption of financial statements.
• Ordinary: Re-appointment of retiring director.
• Ordinary: Appointment and remuneration of statutory auditors.
• Special: No additional remuneration to managing director.
• Special: Commission payable to non-executive independent directors.
• Ordinary: Approval of material related party transactions with Strides Pharma Science Limited.
• Ordinary: Approval of material related party transactions with Strides Pharma subsidiaries.

Voting Outcomes

• All resolutions passed; margins varied, with some dissent in certain resolutions.

Director & Auditor Changes

• Retiring director re-appointed.
• Statutory auditors appointed; remuneration approved.

Material Related Party Transactions

• Approval granted for related party transactions with Strides Pharma Science Limited and subsidiaries.

Material related party transactions

• Addendum to AGM Notice discloses approval of material RPTs with Strides Pharma Science Limited.
• Strides Pharma Inc., USA, Wholly Owned Subsidiary, is party to the RPTs.
• Audit Committee has reviewed CEO/CFO certificates as required under RPT Industry Standards.
• AGM scheduled 23 September 2026; addendum forms part of AGM Notice dated 24 July 2026.
• Notice available on company and stock exchange websites.

Event details

• Analyst/institutional meeting scheduled for September 3, 2026 at Unit II, Bengaluru.
• Latest Investor Presentation uploaded on the company website.

Key disclosures

• Subject: Submission of Business Responsibility & Sustainability Report for FY26 under SEBI LODR.
• Assurance: SGS India provided reasonable assurance over core indicators; scope covers five plants and corporate.
• Boundary: Standalone reporting; five plants plus corporate office; 100% turnover from pharma manufacturing.
• GHG: Scope 1 10,063.96 tCO2e; Scope 2 4,772.50; Scope 3 74,414.37; total intensity 1.06.
• Water: total 3,194.71 kL; intensity 0.23 per turnover; CETP enables zero discharge.
• Waste: total 838.114 t; recycled 541.69; incineration 260.04; landfill 36.38; waste intensity 0.060.
• Governance: ESG Committee and Risk Management Committee oversee sustainability; MD is KMP; board oversight.
• Board female directors: 1 of 8 (13%); KMP female: 1 of 3 (33%).
• Related party transactions: purchases from related parties 2.38%; sales to related parties 29.12%.
• CSR: total spend ₹2,15,79,294 across multiple projects; key initiatives including Anganwadi, Namma Clinics.

Financial performance

• FY26 revenue ₹14,216m; down 2% YoY.
• FY26 EBITDA ₹3,042m; margin 21%.
• Adjusted PAT ₹739m; Adjusted EPS ₹6.5.

Capex & capital allocation

• Capex US$100m; ~80% committed.
• Funded via diversified banking partners; borrowing cost below 9%.

Geography & customers

• 80+ global customers.
• 50+ two-project customers.
• 70% project wins from existing customers.

Governance & audit

• New statutory auditor: BSR & Co LLP for five years.
• SGS India independent assurance on BRSR core indicators.

Meeting Details

• Date: September 3, 2026; time not disclosed.
• Type & mode: Group Investor Meeting, physical.
• Location: OneSource Unit 2 Manufacturing Facility, Bengaluru Rural District, India.
• Organizer: OneSource Specialty Pharma Limited.

Participants

• Company representatives to participate, including Company Secretary and Compliance Officer.

Purpose

• Discuss publicly available information: business overview, strategy, industry trends, growth outlook.

Additional Notes

• UPSI not proposed to be shared.